Q-omics provides the consensus-scored TTC24 profile across patient tissues and cancer cell-line models. TTC24 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TTC24 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, TTC24 RNA expression shows 16,059 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BLCA, KIRC, and DLBC as cancer lineages where TTC24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC24 survival associations across molecular data types. TTC24 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC24 RNA expression–survival associations across cancer types. High TTC24 expression shows unfavorable associations in KIRP, but favorable associations in BLCA, SKCM, HNSC, SCLC and CESC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TTC24 RNA expression.
This table summarizes TTC24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TTC24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC24 shows lower tumor expression in THCA and higher tumor expression in KIRC, LUAD, HNSC, STAD and BRCA. The KIRC box plot shows higher TTC24 RNA expression in tumor versus normal tissue (log2 FC = +0.325, t-test p < 0.001).
This table shows molecular features associated with TTC24 in patient tissues and cancer cell lines. In patient samples, TTC24 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
